Avion Pharmaceuticals launches prescription supplements Prenate Enhance and Prenate Restore
ATLANTA — Avion Pharmaceuticals on Tuesday announced the launch of two advanced vitamin formulations as the newest additions to the Prenate Vitamin Family — Prenate Enhance and Prenate Restore.
The new prescription supplements have been designed to support important nutritional supplementation for women during their prenatal and postpartum period, as well as provide the optimal level of vitamins and minerals recommended.
"Avion is excited to be a leader in innovation for the women’s health category by providing two new prescription supplements that have been formulated based on expert recommendations for nutritional supplementation for women both pregnant and postpartum," stated Mike Sullivan, VP sales and marketing for Avion Pharmaceuticals. "Prenate Enhance and Prenate Restore were designed for nutritional support for both moms and babies during this important period in their life."
Prenate Enhance and Prenate Restore are advanced prescription dietary supplements designed for enhanced absorption with ingredients selected for their high absorbability.
Prenate Restore, the first prescription postnatal dietary supplement with probiotics, designed for postpartum supplementation, helps support the needs of both moms and babies post-pregnancy when nutritional stores can often be depleted.
Prenate Enhance and Prenate Restore provide the highest DHA content (400 mg) among leading prescription prenatal and postnatal vitamins, according to the company, and also include Formical (calcium formate), a patented form of calcium that is better absorbed than calcium citrate and calcium carbonate. And both products provide proprietary Quatrefolic, a source of folate that is approximately seven times more bioavailable than folic acid.
HealthSpot, MedAvail Technologies team up to enhance telehealth
DUBLIN, Ohio — HealthSpot has formed a strategic partnership with MedAvail Technologies, which created the MedAvail MedCenter telepharmacy kiosk, to enable HealthSpot station locations to provide pharmacy services in addition to acute care telehealth services in locations where there is no retail pharmacy, such as employer sites and community locations.
The HealthSpot station — a private, walk-in kiosk that enables patients’ immediate access to medical diagnostics from doctors via high-definition videoconferencing and interactive, digital telehealth tools — could now be co-located with a MedAvail MedCenter telepharmacy kiosk, which is currently in pilot phase at locations in Illinois.
The MedCenter could support the dispensing of prescription drugs and OTC medications through live, two-way conferencing with a pharmacist after a visit with a provider inside the HealthSpot station. At the completion of the Healthspot visit, the provider has the ability to send an e-prescription to the MedAvail MedCenter for fulfillment.
"HealthSpot is dedicated to increasing accessibility while creating a truly integrated healthcare experience for the consumer. This experience means being able to receive care from a provider and then easily be able to fill the prescribed meds after the visit and consult with a pharmacist if needed. MedAvail allows consumers to get pharmacy services in non-pharmacy locations and is the perfect addition to HealthSpot’s platform for extended reach of convenient, affordable health care across the country," stated Steve Cashman, founder and CEO of HealthSpot.
"The cooperation we have with HealthSpot will have a significant positive impact on accessibility and health outcomes for consumers," added Ed Kilroy, CEO of MedAvail Technologies. "We believe innovative telehealth solutions like HealthSpot have a consumer-centric edge that pairs well with our vision to bridge the gap for consumers needing pharmacy services."
Cuomo supports Binghamton University’s pharmacy school
BINGHAMTON, N.Y. — New York Gov. Andrew Cuomo is set to include $10 million in his 2014-2015 executive budget proposal for Binghamton University to commence site acquisition and design work for a School of Pharmaceutical Sciences and Pharmacy.
"We all have been talking about a School of Pharmaceutical Sciences and Pharmacy and Harvey, the governor and I have had a number of conversations about moving forward and accelerating it," State Sen. Thomas W. Libous said. "The governor has reached out to me that he will be putting $10 million into his budget proposal on Tuesday, part of an overall $60 million investment. We see this as a couple-year process, but we believe that with the governor’s support we’re on a fast track. He made it very clear to me that this is the real deal."
The school will most likely be built in Johnson City, N.Y., Libous added. Upon completion, the building is expected to be about 70,000 gross sq. ft.
"Our current plan is to have 300 students when we’re fully enrolled — 240 DPharm students and another 60 PhD students when we’re up and running," Binghamton University President Harvey Stenger said. "We’ll initially hire about 12 clinical and 12 research faculty, and with the additional graduate students, it will make a nice community, create jobs and attract research dollars."
Binghamton submitted a Letter of Intent to SUNY to establish the school back in September 2013. A full proposal will be submitted this spring. The approval will allow Binghamton to develop the second public school of pharmacy in the state of New York.